Periodic Reporting for period 1 - RESPIRE (Development of the first oral disease-modifying treatment for chronic obstructive pulmonary disease (COPD))

Palobiofarma is a Spanish biotech company discovering new treatments for respiratory diseases based on adenosine receptor modulation. Our compound PBF-680 is currently being developed as a first-in-class disease modifying therapy for COPD, the third cause of death worldwide...